• Users Online: 64
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 10  |  Issue : 5  |  Page : 230-237

Clinical management and suggested treatment for COVID-19 in the Indian sub-continent: A comparative study


1 Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Selangor, Malaysia
2 Department of Mechanical and Production Engineering, Islamic University of Technology, Gazipur, Bangladesh
3 Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh
4 Managing Director, The IBN SINA Pharmaceutical Industry Ltd, Dhaka, Bangladesh
5 Department of Physiotherapy, Bangladesh Health Professions Institute, Dhaka, Bangladesh
6 Lecturer of Accounting, Bangamata Sheikh Fojilatunnesa Mujib Science & Technology University, Jamalpur, Bangladesh

Correspondence Address:
Md Insiat Islam Rabby
Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Seri Kembangan, Selangor
Malaysia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/cmrp.cmrp_21_20

Rights and Permissions

SARS-CoV-2 is a dangerous virus which first emerged in China in December 2019. Till now, it has affected more than 4215,497 people in 212 countries and territories. No drug or vaccine is currently recommended, but scientists and researchers are trying their best to identify potential medications and clinical management practices for this virus. The aim of this paper is to find and compare clinical management practices and suggest potential treatment options for COVID-19 in highly infected countries of the Indian sub-continent (India, Bangladesh and Pakistan). Necessary information has been collected from various clinical management guidelines for COVID-19, available at the health ministry websites of India, Bangladesh and Pakistan. Although clinical management practices vary from country to country, all of these countries utilise mechanical ventilation. Moreover, some potential drugs have been suggested by all countries that may be utilised for treatment but did not recommend any of the medications yet because all of them are under evaluation in various clinical trials. Hydroxychloroquine has been suggested by all of these countries but in different situations. All countries are trying their best to follow their government guidelines. In addition, it has been found that the recovery rate of patients from Bangladesh, India and Pakistan is 18.08%, 30.76% and 26.58%, respectively. Although all the suggested treatment protocols have potentiality against COVID-19, they can only be recommended in the treatment procedure after necessary experiments and investigations.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1515    
    Printed24    
    Emailed2    
    PDF Downloaded74    
    Comments [Add]    
    Cited by others 1    

Recommend this journal